Publications by authors named "Shan-Lian Hu"
About 10 million people in China are infected with hepatitis C virus (HCV), with the seroprevalence of anti-HCV in the general population estimated at 0.6%. Delaying effective treatment of chronic hepatitis C (CHC) is associated with liver disease progression, cirrhosis, hepatocellular carcinoma, and liver-related mortality.
View Article and Find Full Text PDFArticle Synopsis
- The China National Formulary (CNF), also called the National Reimbursement Drug List (NRDL), was established in 2000 and updated in 2017 to improve access to reimbursable drugs for 52% of China's population under urban health insurance.
- A pilot project initiated in 2017 aimed at negotiating prices for innovative, expensive drugs not included in the CNF, achieving an 81.8% agreement rate between the government and pharmaceutical companies for 44 medications.
- The authors emphasize the need for future improvements to the CNF’s processes, such as refining evaluation criteria, standardizing documentation formats, and enhancing the professionalism of those conducting evaluations.
Objectives: The goal of this study was to provide a comprehensive analysis of the potential health impact of universal vaccination of infants with the 7-valent pneumococcal conjugate vaccine (PCV7) in China.
Methods: A decision-analytic model designed for pneumococcal disease and outcomes of pneumococcal infection was populated with local age-specific incidence and mortality data to estimate the expected health benefits of vaccinating birth cohorts of approximately 16 million infants per year over a 10-year time horizon in China. The model incorporates both the direct impact on vaccinated children and the indirect effect of herd protection on unvaccinated children and adults.
Objective: To evaluate the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population.
Methods: A randomized, open, control trial was conducted from Nov. 2002 to Feb.